Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7450

Shown on this page

Current sort

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Colorado Anschutz

Live official records

Open in full search

Conditions: Parkinson Disease
Interventions: aDBS; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 843
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 550 more

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Active Surveillance; Device · Other
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Murrieta, California + 23 more

Conditions: Metastatic Solid Tumors
Interventions: ERAS-0015, ERAS-0015 in combination; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Santa Rosa, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: Inavolisib, Enzalutamide, Abiraterone, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Interventions: Valemetostat Tosylate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 10 more

Conditions: Melanoma
Interventions: fianlimab, cemiplimab, relatlimab+nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 106
States / cities: Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Methamphetamine Use Disorder
Interventions: Sham TMS, Active TMS; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 81
States / cities: Phoenix, Arizona • La Jolla, California • Madera, California + 60 more

Conditions: High Grade Myelodysplastic Syndromes
Interventions: Omacetaxine, Azacitidine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 24 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 3 more

Clinical trials in Aurora, Colorado

Filter and sort this location

Institutions in Aurora

Live official records

Adaptive DBS to Offset STN Dysregulation During Exercise in PD

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

WATER IV PCa (AS Sub-study)

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy